Blood Cancer Journal - Table of Contents alert Volume 8 June 2018

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS Volume 8 (June 2018) In this issue Correspondence Article Current Treatment Algorithm   Correspondence   NS-018 reduces myeloma cell proliferation and suppresses osteolysis through inhibition of the JAK2 and Src signaling pathways Ayumi Honda, Kazuya Kuramoto, Tomoko Niwa & Haruna Naito Blood Cancer Journal 2018 8: 10.1038/s41408-018-0098-z Abstract | Full Text Association of MICA and MICB polymorphisms with the susceptibility of leukemia in Korean patients In-Cheol Baek, Dong-Hwan Shin, Eun-Jeong Choi, Hyoung-Jae Kim, Jae-Ho Yoon et al. Blood Cancer Journal 2018 8: 10.1038/s41408-018-0092-5 Abstract | Full Text Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis Mythri Mudireddy, Naseema Gangat, Curtis A. Hanson, Rhett P. Ketterling, Animesh Pardanani et al. Blood Cancer Journal 2018 8: 10.1038/s41408-018-0095-2 Abstract | Full Text Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates? Amer M. Zeidan, Maximilian Stahl, Michelle DeVeaux, Smith Giri, Scott Huntington et al. Blood Cancer Journal 2018 8: 10.1038/s41408-018-0081-8 Abstract | Full Text Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea Rossella Renso, Andrea Aroldi, Pietro Pioltelli, Carlo Gambacorti-Passerini & Elena Maria Elli Blood Cancer Journal 2018 8: 10.1038/s41408-018-0091-6 Abstract | Full Text Impact of blood count recovery on outcomes of acute myeloid leukemia patients achieving morphologic leukemia-free state Wen-Yan Cheng, Yong-Mei Zhu, Zhao Liu, Xiang-Qin Weng, Jing-Ni Sui et al. Blood Cancer Journal 2018 8: 10.1038/s41408-018-0094-3 Abstract | Full Text Risk factors for venous thromboembolism in patients with lymphoma requiring hospitalization Stefan Hohaus, Maria Chiara Tisi, Francesca Bartolomei, Annarosa Cuccaro, Elena Maiolo et al. Blood Cancer Journal 2018 8: 10.1038/s41408-018-0096-1 Abstract | Full Text Dominant cytotoxic NK cell subset within CLPD-NK patients identifies a more aggressive NK cell proliferation Gregorio Barilà, Antonella Teramo, Giulia Calabretto, Chiara Ercolin, Elisa Boscaro et al. Blood Cancer Journal 2018 8: 10.1038/s41408-018-0088-1 Abstract | Full Text Rare variants in Fanconi anemia genes are enriched in acute myeloid leukemia Kyaw Ze Ya Maung, Paul J. Leo, Mahmoud Bassal, Debora A. Casolari, James X Gray et al. Blood Cancer Journal 2018 8: 10.1038/s41408-018-0090-7 Abstract | Full Text Article   CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies Ayed O. Ayed, Annalisa Chiappella, Levi Pederson, Betsy R. Laplant, Angela Giovanna Congiu et al. Blood Cancer Journal 2018 8: 10.1038/s41408-018-0097-0 Abstract | Full Text Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance Jingru Zhang, Yingqiao Wang, Jianxiang Wang, Jianda Hu, Suning Chen et al. Blood Cancer Journal 2018 8: 10.1038/s41408-018-0093-4 Abstract | Full Text Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay Andrew M. Intlekofer, Erel Joffe, Connie L. Batlevi, Patrick Hilden, Jie He et al. Blood Cancer Journal 2018 8: 10.1038/s41408-018-0089-0 Abstract | Full Text Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria Arjun Lakshman, S. Vincent Rajkumar, Francis K. Buadi, Moritz Binder, Morie A. Gertz et al. Blood Cancer Journal 2018 8: 10.1038/s41408-018-0077-4 Abstract | Full Text Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia Isabelle Laverdière, Meaghan Boileau, Andrea L. Neumann, Héloïse Frison, Amanda Mitchell et al. Blood Cancer Journal 2018 8: 10.1038/s41408-018-0087-2 Abstract | Full Text The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting Valerio De Stefano, Bianca Rocca, Alberto Tosetto, Denise Soldati, Giovanna Petrucci et al. Blood Cancer Journal 2018 8: 10.1038/s41408-018-0078-3 Abstract | Full Text Current Treatment Algorithm   Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018 Guido Finazzi, Valerio De Stefano & Tiziano Barbui Blood Cancer Journal 2018 8: 10.1038/s41408-018-0100-9 Abstract | Full Text Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms Valerio De Stefano, Guido Finazzi & Tiziano Barbui Blood Cancer Journal 2018 8: 10.1038/s41408-018-0101-8 Abstract | Full Text Advertisement Nature Briefing is an essential round-up of science news, opinion and analysis, free in your inbox every weekday. With Nature Briefing, we'll keep you updated on the latest research, so you can focus on yours. Click here to sign up. Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Blood Cancer Journal. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Springer Nature's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2018 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.